Pegcetacoplan

In this Healio Video Perspective from Angiogenesis, Exudation, and Degeneration 2024, Roger A. Goldberg, MD, MBA, discusses 3-year data investigating pegcetacoplan for the treatment of geographic atrophy.

The Committee for Medicinal Products for Human Use of the European Medicines Agency issued a negative opinion on a marketing authorization application for pegcetacoplan, according to an Apellis Pharmaceuticals press release.

WAILEA, Hawaii — Clinicians need to balance the efficacy of geographic atrophy medications with the risks, according to a speaker at Retina 2024.

In this video, Esther M. Bowie, MD, discusses the results of the GATHER2 trial, presented at the American Academy of Ophthalmology meeting.

In this video, Esther M. Bowie, MD, discusses results of the GALE study, presented at the American Academy of Ophthalmology meeting.

ROME — In this Healio Video Perspective from the FLORetina-ICOOR meeting, Caroline Baumal, MD, presents data from the GALE study on pegcetacoplan for geographic atrophy in macular degeneration.

In this video, Arshad M. Khanani, MD, MA, FASRS, discusses the results of the phase 2 ARCHER trial of ANX007 from Annexon Biosciences in patients with geographic atrophy, presented at the American Academy of Ophthalmology meeting.

In this video, Yasha S. Modi, MD, discusses the 2-year results of the GATHER2 trial, which showed that avacincaptad pegol had a positive effect on geographic atrophy reduction.

In this video, Yasha S. Modi, MD, discusses 3-year data from the GALE extension study on pegcetacoplan for the treatment of geographic atrophy, presented at the American Academy of Ophthalmology meeting.

In this video, Yasha S. Modi, MD, discusses the Charles L. Schepens, MD, Lecture presented at the American Academy of Ophthalmology meeting by Emily Y. Chew, MD, on macular telangiectasia.